AstraZeneca PLC (AZN) Meet the Management at ESMO 2024 Conference (Transcript)
Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ETCompany ParticipantsPascal Soriot - Chief ...
Armed robbery in Revesby10d
Dana-Farber to Lead ESMO Congress 2024 with Top Research
Innovations in breast cancer, targeted therapies, antibody-drug conjugates, and kidney cancerNovel treatments, including ...
Business Wire6d
Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic ...
These data are being presented today at the 2024 European Society for Medical Oncology Congress (ESMO 2024) during the Proffered Paper Session: GU Tumours, Prostate at 2:45 p.m. CEST. “Despite recent ...
oncnursingnews7d
Tivozanib Alone Outperforms Lower-Dose Tivozanib-Nivolumab Combo in Metastatic RCC
Study findings support tivozanib monotherapy for second-line treatment of certain patients with metastatic RCC, an expert ...
Medscape4d
Pembrolizumab Plus Chemoradiotherapy Provides Significant Survival Benefit in Cervical Cancer
Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...
The American Journal of Managed Care7d
Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials
In presentations at European Society for Medical Oncology (ESMO) Congress 2024 ... thoracic medical oncologist at MedStar Georgetown University Hospital and assistant professor at Georgetown ...
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
Trial investigating Cabometyx® (cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for one of the ...